Pliant Therapeutics, Inc.
PLRX
$1.15
$0.021.32%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -46.73% | -47.17% | -47.05% | -27.55% | -10.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.66% | -63.06% | -60.47% | -54.58% | -24.81% |
| Operating Income | 47.66% | 63.06% | 60.47% | 54.58% | 24.81% |
| Income Before Tax | 48.33% | 64.32% | 52.59% | 54.47% | 22.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.33% | 64.32% | 52.59% | 54.47% | 22.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.33% | 64.32% | 52.59% | 54.47% | 22.48% |
| EBIT | 47.66% | 63.06% | 60.47% | 54.58% | 24.81% |
| EBITDA | 47.70% | 63.23% | 60.82% | 54.89% | 24.78% |
| EPS Basic | 48.78% | 64.65% | 53.05% | 54.97% | 23.74% |
| Normalized Basic EPS | 48.79% | 64.65% | 61.67% | 55.14% | 23.73% |
| EPS Diluted | 48.78% | 64.65% | 53.05% | 54.97% | 23.74% |
| Normalized Diluted EPS | 48.79% | 64.65% | 61.67% | 55.14% | 23.73% |
| Average Basic Shares Outstanding | 0.87% | 0.95% | 0.98% | 1.11% | 1.66% |
| Average Diluted Shares Outstanding | 0.87% | 0.95% | 0.98% | 1.11% | 1.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |